A Prescription Event Monitoring (PEM) Study to Evaluate the Effects of Adjuvant Therapy with ZincorespTM Tablets in Patients Having Recurrent Respiratory Disorders and Infections. - NA

apex laboratories private limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1.Age above 18 years of any gender.
•2.Patients who are willing to give consent for the child’s participation in study.
•3. Patients having recurrent episodes of any of the following
•-Fever associated with respiratory tract infections (RTI)
•- URTI (rhinitis, pharyngitis, laryngitis, influenza)-
•LRTI (pneumonia, bronchitis, and bronchiolitis)
•-Bronchial asthma
•-SARS-CoV-2
•-Combined allergic rhinitis and asthma syndrome (CARAS)
•-Pulmonary tuberculosis

•1.Any evidence of malignancy.
•2.History and clinical findings suggestive of metabolic diseases
•3.History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
•4.History of respiratory tract surgery.
•5.Known diagnosis of congenital cardiac defects.

发起方